Tandem mass spectrometer

描述（由申请人提供）：质谱法在生物分子研究中的应用已经彻底改变了生物医学研究的许多方面。美国国立卫生研究院支持的18个研究小组位于umdnj -罗伯特伍德约翰逊医学院和罗格斯大学，新泽西州立大学皮斯卡塔韦校区，正在申请一个配备纳米喷雾界面和毛细管高效液相色谱系统的ThermoFinnigan Deca XP Plus质谱仪，以补充我们现有的共享MALDI-TOF质谱资源。用户组成员建议使用该仪器进行生物医学相关的描述性和差异性蛋白质组学研究、从头蛋白质测序、蛋白质鉴定、翻译后修饰鉴定、交联分析以及物理和结构生物学研究。用户组的许多成员目前将质谱法作为其研究的一个组成部分。然而，目前大多数必须将样品送到其他设施进行分析，这对及时实现研究目标造成了障碍。此外，一些用户需要直接访问LC/MS/MS系统进行蛋白质分析，而校园内没有可用的资源。因此，所有用户都将因拥有所要求的仪器而获益匪浅。这将导致生产力的显著提高。更重要的是，这种资源将使研究人员能够在新的方向上扩展他们的研究，并开始以前无法进行的新项目。

DESCRIPTION (provided by applicant): The application of mass spectrometry to the study of biological molecules has revolutionized many aspects of biomedical research. A group of eighteen NIH-supported research groups located at UMDNJ-Robert Wood Johnson Medical School and Rutgers, the State University of New Jersey Piscataway Campus) are requesting a ThermoFinnigan Deca XP Plus mass spectrometer equipped with a nanospray interface and capillary HPLC system to complement our existing shared MALDI-TOF mass spectrometry resource. The user group members propose to use this instrument to perform biomedically relevant descriptive and differential proteomics studies, de novo protein sequencing, and protein identification, identification of posttranslational modifications, cross-linking analysis, as well as physical and structural biology studies. Many members of the User Group currently employ mass spectrometry as an integral part of their research. However, most currently must send samples to other facilities for analysis, creating a barrier to the timely accomplishment of research goals. In addition, some of the users require direct access to a LC/MS/MS system for protein analysis and there is no available resource on campus. All of the users would therefore benefit enormously from having the requested instrument. This would result in significant increases in productivity. More importantly, this resource will allow the investigators to expand their research in new directions, and to begin new projects that could not have previously been undertaken.